Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Fibroblast Growth Factor Receptor”

75 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 75 results

Testing effectiveness (Phase 2)Enrolling By InvitationNCT07393373
What this trial is testing

Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

Who this might be right for
Hypochondroplasia
QED Therapeutics, a BridgeBio company 135
Large-scale testing (Phase 3)Study completedNCT03410693
What this trial is testing

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Carcinoma, Transitional Cell
Bayer 175
Not applicableStudy completedNCT04035811
What this trial is testing

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 271
Testing effectiveness (Phase 2)Study completedNCT04083976
What this trial is testing

Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

Who this might be right for
Advanced Solid Tumor
Janssen Research & Development, LLC 316
Testing effectiveness (Phase 2)Ended earlyNCT04003610
What this trial is testing

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Who this might be right for
Metastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
Incyte Corporation 7
Testing effectiveness (Phase 2)Study completedNCT01676714
What this trial is testing

Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer

Who this might be right for
Non-Small Cell Lung CancerColorectal Cancer
University of California, Davis 10
Large-scale testing (Phase 3)Study completedNCT06164951
What this trial is testing

Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 114
Early research (Phase 1)Looking for participantsNCT06625593
What this trial is testing

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
BeOne Medicines 168
Early research (Phase 1)Study completedNCT01928459
What this trial is testing

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Solid Tumors
Novartis Pharmaceuticals 62
Large-scale testing (Phase 3)Study completedNCT05052801
What this trial is testing

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Amgen 547
Testing effectiveness (Phase 2)Looking for participantsNCT06511648
What this trial is testing

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Who this might be right for
Muscle-invasive Bladder Cancer
Spanish Oncology Genito-Urinary Group 90
Testing effectiveness (Phase 2)Study completedNCT03797326
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Who this might be right for
Advanced Solid TumorsTriple Negative Breast CancerOvarian Cancer+5 more
Merck Sharp & Dohme LLC 611
Testing effectiveness (Phase 2)Ended earlyNCT01732107
What this trial is testing

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

Who this might be right for
Bladder Cancer
Noah Hahn, M.D. 13
Early research (Phase 1)Ended earlyNCT03144661
What this trial is testing

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Who this might be right for
Hepatocellular Carcinoma (HCC)CholangiocarcinomaEsophageal Cancer+3 more
Incyte Corporation 25
Not applicableApproved For MarketingNCT03825484
What this trial is testing

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Who this might be right for
Advanced Cancers and FGFR Genetic Alterations
Janssen Scientific Affairs, LLC
Early research (Phase 1)Ended earlyNCT02368951
What this trial is testing

Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)

Who this might be right for
Medical Oncology
Bayer 20
Not applicableStudy completedNCT03955913
What this trial is testing

Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

Who this might be right for
Urothelial CancerReceptors, Fibroblast Growth Factor
Janssen Research & Development, LLC 3,679
Large-scale testing (Phase 3)Enrolling By InvitationNCT06873035
What this trial is testing

An Interventional Study of Infigratinib in Children With Hypochondroplasia

Who this might be right for
Hypochondroplasia
QED Therapeutics, a BridgeBio company 24
Large-scale testing (Phase 3)Ended earlyNCT03773302
What this trial is testing

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Who this might be right for
Advanced CholangiocarcinomaFGFR2 Gene Mutation
QED Therapeutics, a BridgeBio company 48
Testing effectiveness (Phase 2)Ended earlyNCT01367275
What this trial is testing

Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

Who this might be right for
Colorectal CancerColorectal Adenocarcinoma
M.D. Anderson Cancer Center 8
Next Page